116 related articles for article (PubMed ID: 19381990)
1. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
Henderson RJ; Leon CG; Wasan KM
Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
[TBL] [Abstract][Full Text] [Related]
2. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.
Patankar N; Wasan KM
Pharm Res; 2006 May; 23(5):1020-4. PubMed ID: 16715392
[TBL] [Abstract][Full Text] [Related]
3. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
[TBL] [Abstract][Full Text] [Related]
6. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
[TBL] [Abstract][Full Text] [Related]
7. Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.
Sivak O; Lau B; Patankar N; Wasan KM
Pharm Res; 2004 Dec; 21(12):2336-9. PubMed ID: 15648266
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
9. Interfacial and lipid transfer properties of human phospholipid transfer protein: implications for the transfer mechanism of phospholipids.
Setälä NL; Holopainen JM; Metso J; Wiedmer SK; Yohannes G; Kinnunen PK; Ehnholm C; Jauhiainen M
Biochemistry; 2007 Feb; 46(5):1312-9. PubMed ID: 17260960
[TBL] [Abstract][Full Text] [Related]
10. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
Bellmann R; Egger P; Wiedermann CJ
Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
[No Abstract] [Full Text] [Related]
11. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
12. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
Ramos H; Brajtburg J; Marquez V; Cohen BE
Drugs Exp Clin Res; 1995; 21(6):211-6. PubMed ID: 8907695
[TBL] [Abstract][Full Text] [Related]
14. Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma.
Henderson RJ; Wasan KM; Leon CG
Lipids Health Dis; 2009 Jul; 8():27. PubMed ID: 19627602
[TBL] [Abstract][Full Text] [Related]
15. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
16. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid transfer protein is present in human tear fluid.
Jauhiainen M; Setälä NL; Ehnholm C; Metso J; Tervo TM; Eriksson O; Holopainen JM
Biochemistry; 2005 Jun; 44(22):8111-6. PubMed ID: 15924430
[TBL] [Abstract][Full Text] [Related]
18. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
Ruijgrok EJ; Vulto AG; Van Etten EW
J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
[TBL] [Abstract][Full Text] [Related]
19. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane.
Shimizu K; Osada M; Takemoto K; Yamamoto Y; Asai T; Oku N
J Control Release; 2010 Jan; 141(2):208-15. PubMed ID: 19815038
[TBL] [Abstract][Full Text] [Related]
20. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA.
Desrumaux C; Athias A; Bessède G; Vergès B; Farnier M; Perségol L; Gambert P; Lagrost L
Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):266-75. PubMed ID: 9974406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
